搜索
CorMedix Inc
CRMD添加自选
7.550USD
-0.380-4.79%
收盘 05/15, 16:00（美东）报价延迟15分钟
591.88M总市值
3.10市盈率 TTM
关于 CorMedix Inc 公司
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
CorMedix Inc简介
公司代码CRMD
公司名称CorMedix Inc
上市日期Mar 25, 2010
CEOTodisco (Joseph)
员工数量64
证券类型Ordinary Share
年结日Mar 25
公司地址300 Connell Drive
城市BERKELEY HEIGHTS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编07922
电话19085179500
网址https://cormedix.com/
公司代码CRMD
上市日期Mar 25, 2010
CEOTodisco (Joseph)
CorMedix Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
401.08K
-41.48%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
132.74K
+47.50%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
38.47K
-14.17%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
38.33K
-14.23%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
36.00K
-15.15%
Mr. Myron M. Kaplan, J.D.
Mr. Myron M. Kaplan, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
401.08K
-41.48%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
132.74K
+47.50%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
38.47K
-14.17%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
38.33K
-14.23%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
36.00K
-15.15%
收入明细
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
311.71M
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 5月14日 周四
更新时间: 5月14日 周四
持股股东
股东类型
持股股东
持股股东
占比
Deep Track Capital LP
6.72%
BlackRock Institutional Trust Company, N.A.
6.45%
Abdalkader (Shaibatalhamd Aymen)
5.86%
Vanguard Capital Management, LLC
3.99%
Marshall Wace LLP
2.51%
其他
74.47%
持股股东
持股股东
占比
Deep Track Capital LP
6.72%
BlackRock Institutional Trust Company, N.A.
6.45%
Abdalkader (Shaibatalhamd Aymen)
5.86%
Vanguard Capital Management, LLC
3.99%
Marshall Wace LLP
2.51%
其他
74.47%
股东类型
持股股东
占比
Investment Advisor
27.10%
Investment Advisor/Hedge Fund
13.41%
Hedge Fund
10.76%
Individual Investor
7.51%
Research Firm
2.29%
Pension Fund
0.83%
Bank and Trust
0.39%
Insurance Company
0.03%
其他
37.68%
机构持股
更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
390
43.28M
55.17%
-18.63M
2025Q4
338
43.86M
55.93%
+10.78K
2025Q3
340
43.85M
56.33%
+8.67M
2025Q2
304
34.76M
43.08%
+9.67M
2025Q1
267
24.95M
43.35%
-4.41M
2024Q4
241
23.99M
39.87%
+4.76M
2024Q3
216
19.17M
36.31%
+1.94M
2024Q2
207
17.23M
38.40%
-272.84K
2024Q1
207
17.37M
41.54%
-5.46M
2023Q4
207
18.82M
39.64%
+838.41K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Deep Track Capital LP
5.27M
6.67%
+318.59K
+6.43%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
5.06M
6.4%
+15.47K
+0.31%
Dec 31, 2025
Abdalkader (Shaibatalhamd Aymen)
4.60M
5.82%
-45.63K
-0.98%
Jan 01, 2026
Marshall Wace LLP
1.97M
2.49%
-1.51M
-43.39%
Dec 31, 2025
State Street Investment Management (US)
1.92M
2.43%
+85.24K
+4.64%
Dec 31, 2025
Geode Capital Management, L.L.C.
1.91M
2.42%
+102.46K
+5.66%
Dec 31, 2025
UBS Financial Services, Inc.
627.53K
0.79%
-453.11K
-41.93%
Dec 31, 2025
Deerfield Management Company, L.P.
1.11M
1.4%
-2.22M
-66.67%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Invesco Biotechnology & Genome ETF
1.87%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.52%
VictoryShares Small Cap Free Cash Flow ETF
0.79%
First Trust Active Factor Small Cap ETF
0.3%
Janus Henderson Small Cap Growth Alpha ETF
0.25%
ALPS Barron's 400 ETF
0.21%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.19%
Vanguard US Multifactor ETF
0.16%
iShares Micro-Cap ETF
0.15%
查看更多
State Street SPDR S&P Pharmaceuticals ETF
占比2.01%
Invesco Biotechnology & Genome ETF
占比1.87%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.52%
VictoryShares Small Cap Free Cash Flow ETF
占比0.79%
First Trust Active Factor Small Cap ETF
占比0.3%
Janus Henderson Small Cap Growth Alpha ETF
占比0.25%
ALPS Barron's 400 ETF
占比0.21%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0.19%
Vanguard US Multifactor ETF
占比0.16%
iShares Micro-Cap ETF
占比0.15%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
